These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24909153)

  • 21. Genome-based vaccines.
    Knaust A; Frosch M
    Int J Med Microbiol; 2004 Oct; 294(5):295-301. PubMed ID: 15532988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-meningococcal vaccine: myth and reality].
    Nassif X
    Arch Pediatr; 1999; 6 Suppl 3():647s-649s. PubMed ID: 10429807
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anti-meningococcal vaccines].
    Taha MK; Alonso JM
    Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
    Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
    Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
    Xie O; Pollard AJ; Mueller JE; Norheim G
    Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine offers meningitis hope.
    Butler D
    Nature; 2010 Nov; 468(7321):143. PubMed ID: 21068797
    [No Abstract]   [Full Text] [Related]  

  • 28. The implications of vaccines for prevention of bacterial meningitis.
    Riordan A
    Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neisseria: recent advances and future challenges.
    Criss AK; Tang C
    Pathog Dis; 2017 Nov; 75(8):. PubMed ID: 28957453
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
    Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of BC meningococcal vaccine in Brazil.
    Nishioka S
    Int J Epidemiol; 1996 Oct; 25(5):1102-3. PubMed ID: 8921501
    [No Abstract]   [Full Text] [Related]  

  • 32. [New vaccines against group B meningococcal diseases].
    Hietalahti J; Meri S
    Duodecim; 2015; 131(6):525-32. PubMed ID: 26237895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
    Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
    Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.
    Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
    Clin Vaccine Immunol; 2012 Oct; 19(10):1561-6. PubMed ID: 22855388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis.
    Zheng J; Li X; Masci AM; Kahn H; Huffman A; Asfaw E; Pan Y; Guo J; He V; Song J; Seleznev AI; Lin AY; He Y
    J Biomed Semantics; 2024 Jun; 15(1):12. PubMed ID: 38890666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
    Micoli F; Romano MR; Tontini M; Cappelletti E; Gavini M; Proietti D; Rondini S; Swennen E; Santini L; Filippini S; Balocchi C; Adamo R; Pluschke G; Norheim G; Pollard A; Saul A; Rappuoli R; MacLennan CA; Berti F; Costantino P
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19077-82. PubMed ID: 24191022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neisseria proteomics for antigen discovery and vaccine development.
    Christodoulides M
    Expert Rev Proteomics; 2014 Oct; 11(5):573-91. PubMed ID: 25017717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential of the adhesin complex protein of Neisseria meningitidis for next-generation meningococcal vaccines.
    Hung MC; Heckels JE; Christodoulides M
    Expert Rev Vaccines; 2013 Sep; 12(9):981-4. PubMed ID: 24053391
    [No Abstract]   [Full Text] [Related]  

  • 39. Post-licensure safety of the meningococcal group C conjugate vaccine.
    Andrews N; Stowe J; Miller E; Taylor B
    Hum Vaccin; 2007; 3(2):59-63. PubMed ID: 17312400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of emerging vaccines for childhood meningococcal disease.
    Choudhuri D; Huda T; Theodoratou E; Nair H; Zgaga L; Falconer R; Luksic I; Johnson HL; Zhang JS; El Arifeen S; Nelson CB; Borrow R; Campbell H; Rudan I
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S29. PubMed ID: 21501447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.